Kartos Therapeutics

aid: kartos-therapeutics
name: Kartos Therapeutics
description: Kartos Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered at 275
  Shoreline Drive, Redwood City, California, developing navtemadlin (KRT-232), an orally administered, potent and selective
  small-molecule inhibitor of MDM2. The company was founded in 2016 by Wayne Rothbaum, president of Quogue Capital and co-founder
  of Acerta Pharma, around an MDM2 inhibitor in-licensed from Amgen. Navtemadlin blocks the MDM2 protein that suppresses p53,
  restoring p53 function in tumours that retain wild-type TP53 and driving cell-cycle arrest through p21 and apoptosis through
  pro-apoptotic Bcl-2 family proteins. The clinical programme is centred on myelofibrosis and includes the enrolling global
  Phase 3 POIESIS trial of navtemadlin added to ruxolitinib (NCT06479135), the Phase 1b/2 KRT-232-109 combination study (NCT04485260),
  and the completed Phase 3 BOREAS study of navtemadlin versus best available therapy in JAK-inhibitor relapsed or refractory
  myelofibrosis (NCT03662126), with reported activity also in acute myeloid leukaemia and Merkel cell carcinoma. Kartos is
  led by CEO Jesse McGreivy, MD, with Srdan Verstovsek, MD, PhD as chief medical officer, and is backed by Quogue Capital,
  OrbiMed Advisors, Amgen, SR One, Fidelity, BlackRock, T. Rowe Price, Invus and Soleus Capital. Kartos Therapeutics runs
  no developer program and publishes no product API, no developer portal and no API documentation; the only machine-readable
  surface reachable without credentials is the WordPress REST content API behind kartosthera.com, catalogued here.
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: true
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - openapi
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - authentication
  - security
  generated: '2026-11-06'
  method: derived
image: https://kartosthera.com/wp-content/uploads/2025/10/og_kartos-therapeutics.jpg
url: https://raw.githubusercontent.com/api-evangelist/kartos-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Hematology
- Rare Disease
- Precision Medicine
- Clinical Trials
- Life Sciences
- content-api
tags_raw:
- Company
- biotechnology
- pharmaceuticals
- oncology
- hematology
- rare-disease
- precision-medicine
- clinical-trials
- life-sciences
- content-api
apis:
- aid: kartos-therapeutics:kartosthera-com-website-wordpress-rest
  name: Kartos Therapeutics Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Kartos Therapeutics website at kartosthera.com: the route index
    of the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://kartosthera.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://kartosthera.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Overlay
  url: overlays/kartos-therapeutics-content-overlay.yaml
- type: Website
  url: https://kartosthera.com/
- type: About
  url: https://kartosthera.com/about/
- type: Science
  url: https://kartosthera.com/science/
- type: Research
  url: https://kartosthera.com/research/
- type: Presentations
  url: https://kartosthera.com/presentations/
- type: PatientResources
  url: https://kartosthera.com/advocacy/
- type: Contact
  url: https://kartosthera.com/contact/
- type: Support
  url: https://kartosthera.com/contact/
- type: PrivacyPolicy
  url: https://kartosthera.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/kartos-therapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/kartos-therapeutics_stock/
- type: Authentication
  url: authentication/kartos-therapeutics-authentication.yml
- type: Conventions
  url: conventions/kartos-therapeutics-conventions.yml
- type: Conformance
  url: conformance/kartos-therapeutics-conformance.yml
- type: ErrorCatalog
  url: errors/kartos-therapeutics-problem-types.yml
- type: Lifecycle
  url: lifecycle/kartos-therapeutics-lifecycle.yml
- type: DataModel
  url: data-model/kartos-therapeutics-data-model.yml
- type: WellKnown
  url: well-known/kartos-therapeutics-well-known.yml
- type: DomainSecurity
  url: security/kartos-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/kartos-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-04'
  status: enriched
  artifacts_added: 15
  pass: local-v1